Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

Oncolytics Biotech Inc
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oncolytics Biotech Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Oncolytics Biotech Inc
TSX:ONC
Capital Expenditures
-CA$38k
CAGR 3-Years
51%
CAGR 5-Years
-31%
CAGR 10-Years
13%
Theratechnologies Inc
TSX:TH
Capital Expenditures
-$10.1m
CAGR 3-Years
-186%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Capital Expenditures
-$236k
CAGR 3-Years
-7%
CAGR 5-Years
46%
CAGR 10-Years
-13%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Capital Expenditures
-$1.3m
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
-1%
Spectral Medical Inc
TSX:EDT
Capital Expenditures
-CA$194k
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
3%
No Stocks Found

Oncolytics Biotech Inc
Glance View

Market Cap
173.1m CAD
Industry
Biotechnology

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

ONC Intrinsic Value
Not Available

See Also

What is Oncolytics Biotech Inc's Capital Expenditures?
Capital Expenditures
-38k CAD

Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Capital Expenditures amounts to -38k CAD.

What is Oncolytics Biotech Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
13%

Over the last year, the Capital Expenditures growth was 81%. The average annual Capital Expenditures growth rates for Oncolytics Biotech Inc have been 51% over the past three years , -31% over the past five years , and 13% over the past ten years .

Back to Top